Longeveron Inc. Class A Common Stock represents ownership in Longeveron Inc., a clinical-stage biotechnology company focused on regenerative medicine and cellular therapies. The company develops allogeneic medicinal signaling cell-based products designed to address serious pediatric, aging-related, and other life-threatening conditions. Its current programs center on Lomecel-B, a lead investigational therapy being studied across several clinical indications, including hypoplastic left heart syndrome, Alzheimer’s disease, pediatric dilated cardiomyopathy, and aging-related frailty. Longeveron’s work spans cell therapy research, clinical development, and translational medicine, placing it within the broader biotechnology sector. Headquartered in Miami, Florida, Longeveron serves as a specialized player in the market for advanced biological treatments aimed at unmet medical needs.
WebsiteLife Science & Technology Park
Miami, FL, 33136
United States
Longeveron Inc. (NASDAQ:LGVN) reported on September 16 that ELPIS II, its randomized Phase 2b trial in 40 infants with hypoplastic left heart syndrome, missed its primary efficacy endpoint. The study evaluated laromestrocel as an adjunct to Stage 2 palliative heart surgery. The primary endpoint measured change in right ventricular ejection fraction, an indicator of pumping […]
MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference taking place September 14-16, 2026 in New York City. Details for the Company’s presentation: Date:Monday, September 14, 2026 Time:1:00 – 1:30 p.m. ET The webcast for this
Longeveron Announces 1-for-10 Reverse Stock Split
Detailed price information for Longeveron Inc (LGVN-Q) from The Globe and Mail including charting and trades.
Investors talking about LGVN also mention
What share of all stock conversation is about LGVN?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% 0 | 0% 0 | 0% +0 | 0% 0 |
Of the messages about LGVN that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | 100% +85 | 36.96% -47.79 | 75.29% +3.37 | ||
| Bearish | — | 0% -85 | 63.04% +47.79 | 24.71% -3.37 |
Of the messages about LGVN that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | — | — | 96.72% | 41.41% | ||
| Technical Analysis | — | — | 1.64% | 20.91% | ||
| Earnings | — | — | 0% | 1.04% | ||
| Controversies | — | — | 1.64% | 0.21% | ||
| Analysts | — | — | 0% | 19.36% | ||
| Macro | — | — | 0% | 17.08% |
Of the messages about LGVN, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | — | 0% | 61.78% | 36.65% | ||
| Newcomers | — | 100% | 38.22% | 63.35% |